Apolipoprotein (apo-) B mRNA editing is the deamination of cytidine that creates a new termination codon and produces a truncated version of apo-B (apo-B48). The cytidine deaminase catalytic subunit [apo-B mRNA-editing enzyme catalytic polypeptide 1 (APOBEC-1)] of the multiprotein editing complex has been identified. We generated transgenic rabbits and mice expressing rabbit APOBEC-1 in their livers to determine whether hepatic expression would lower low density lipoprotein cholesterol concentrations. The apo-B mRNA from the livers of the transgenic mice and rabbit was extensively edited, and the transgenic animals had reduced concentrations of apo-B100 and low density lipoproteins compared with control animals. Unexpectedly, all of the transgenic mice and a transgenic rabbit had liver dysplasia, and many transgenic mice developed hepatocellular carcinomas. Many of the mouse livers were hyperplastic and filled with lipid. Other hepatic mRNAs with sequence motifs similar to apo-B mRNA were examined for this type of editing (i.e., cytidine deamination). One of these, tyrosine kinase, was edited in livers of transgenic mice but not of controls. This result demonstrates that other mRNAs can be edited by the overexpressed editing enzyme and suggests that aberrant editing of hepatic mRNAs involved in cell growth and regulation is the cause of the tumorigenesis. Finally, these findings compromise the potential use of APOBEC-1 for gene therapy to lower plasma levels of low density lipoproteins.
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Apolipoprotein (apo-) B mRNA editing is the deamination of a specific cytidine (nt 6666) to uridine in the apo-B transcript. This deamination changes a glutamine codon (CAA) to a termination codon (UAA) (1, 2) and results in the formation of an apo-B protein (apo-B48) about one-half the size of the full-length genomically encoded apo-B (apo-B100). In humans, the liver synthesizes apo-B100, the major protein component of plasma (-migrating low density lipoproteins (LDL).
The small intestine produces apo-B48, a protein necessary for the secretion of chylomicrons (3-5). Lipoproteins containing apo-B48 are rapidly cleared from plasma and are not converted to LDL. In most mammals, apo-B mRNA editing occurs only in the small intestine, but in horses, rats, mice, and dogs, editing also occurs in the liver (6). Species with hepatic apo-B mRNA editing possess low plasma LDL concentrations (6), which suggests that expression of this activity in the livers of species lacking hepatic editing could lower LDL concentrations. Thus, induction of the expression of hepatic editing is a potential target for gene therapy to lower LDL and lipoprotein(a) concentrations (7, 8) .
Whether apo-B mRNA editing physiologically modifies other mRNA substrates is unknown. However, if certain sequence motifs in the apo-B mRNA are inserted into a heterologous cDNA, the transcribed chimeric RNA can be edited in vitro (9, 10) . Additionally, the occurrence of editing in cell lines and organs that do not synthesize significant amounts of apo-B suggests that editing may have other biological functions (11-13).
The apo-B mRNA editing enzyme is a multi-subunit complex (14-18). A single subunit that catalyzes the deamination was cloned recently (14) and designated apo-B mRNA-editing enzyme catalytic polypeptide 1 (APOBEC-1) (19). Besides APOBEC-1, one or more additional auxiliary protein components found in the liver and many other organs and cells are necessary for editing in vitro (16) (17) (18) . Thus, in species devoid of hepatic editing activity, the hepatic expression of APO-BEC-1 should be sufficient to generate edited apo-B mRNA.
To study the impact of hepatic apo-B mRNA editing on lipid metabolism and atherogenesis and to study other possible biological roles of apo-B mRNA editing, we developed transgenic mice and rabbits expressing editing activity in their livers.
MATERIALS AND METHODS
Generation of APOBEC-1 Transgenic Mice and Rabbits. A full-length cDNA fragment of rabbit APOBEC-1 was isolated from pREPR (18) by digestion with EcoRI and subcloned into pLivll, which had been linearized with Mun I to produce the vector pLivREPR. An Sal I-Spe I fragment of pLivREPR was gel-purified by Qiaex (Qiagen, Chatsworth, CA) and microinjected into fertilized oocytes of strain ICR mice (Charles River Breeding Laboratories) and New Zealand White rabbits (20) . Founder pups were identified by Southern blot analysis of genomic DNA from mouse tails or rabbit ears with a 32P-labeled probe of rabbit APOBEC-1 cDNA. We estimated the transgene copy number by Southern blot analysis using the endogenous rabbit APOBEC-1 gene as a control.
Northern In Vitro Editing Assay. S100 extracts were prepared from five transgenic mice (1-20) and five age-and sex-matched control mice (21). A total of 5, 25, or 100 gg of S100 liver extract was incubated with substrate apo-B RNA for 2 hr at 30°C and analyzed by primer extension as described (18).
Histological Analysis. Livers were fixed with 4% formaldehyde, embedded with paraffin, and stained with either hematoxylin/eosin or trichrome stain for collagen. Histopathological diagnoses were based upon criteria described by Maronpot et al. (22).
Lipoprotein Analysis. For agarose gel analysis, 2 ,ul of plasma were separated by electrophoresis on a 1% agarose gel and stained by Fat Red 7B. For SDS/PAGE analysis, the d < 1.063 g/ml fraction was isolated from 1 ml of mouse plasma by ultracentrifugation. After dialysis against 5 mM ammonium bicarbonate, one-half of the sample was subjected to 5% SDS/PAGE and stained with Coomassie blue.
RESULTS AND DISCUSSION
To generate transgenic mice and rabbits expressing rabbit APOBEC-1, a full-length rabbit APOBEC-1 cDNA was subcloned into a vector (pLiv1l) containing a promoter, an intron, and a hepatic control region, all from the human apo-E gene. Other heterologous cDNAs previously cloned into this vector were expressed robustly and predominantly in the liver (20). A linearized fragment of this construct was used to generate three transgenic mouse founders and two transgenic rabbit founders. Additionally, transgenic mice were generated using a mutant form of APOBEC-1 that was enzymatically inactive. Four independent transgenic mouse lines (I-20, I-22, I-28L, and I-28H) were established from the three mouse founders expressing wild-type rabbit APOBEC-1, and their transgene copy numbers were estimated to be 7, 17, 3, and 10, respectively (Table 1) . One transgenic rabbit founder had one copy of the transgene, and the other founder had 17 copies. BEC-1 mRNA also were found in the kidneys and heart (data not shown). Primer-extension analysis showed that hepatic apo-B mRNA from the transgenic mouse livers was edited extensively (Fig. 1 ). An average of 92% of apo-B mRNA was edited in the livers of all four transgenic mouse lines (n = 26). In the transgenic mouse line expressing the mutant transgene, no increase in the amount of edited apo-B mRNA (82%, n = 4) was observed over that of the nontransgenic mice (83%, n = 23).
Liver extracts from wild-type APOBEC-1 transgenic mice were 15-fold more active in editing a synthetic apo-B RNA substrate in vitro than liver extracts from age-and sex-matched control mice (Fig. 2) . This finding demonstrated that APO-BEC-1 was overexpressed, resulting in excess editing activity in the transgenic mouse livers. As expected, by agarose gel electrophoresis, 83-migrating lipoproteins (LDL) were not detected in the plasma of the transgenic mice (Fig. 3A) . The apparent lack of apo-B100 in the transgenic mouse lipoproteins was confirmed by SDS/PAGE (Fig. 3B) .
The most striking phenotypic change in the transgenic mice was the finding of enlarged livers due to hepatic dysplasia and hepatocellular carcinoma (Table 1 in the cytoplasm-to-nucleus ratio. Hepatocytes often exhibited a 3-fold nuclear enlargement. There was compression of sinusoidal cells by the thickened plates of hepatocytes that often contained variable amounts of clear, round vacuoles (Fig. 4B) . Oil Red 0 staining revealed these cytoplasmic vacuoles to be filled with lipid droplets (data not shown). In all of the mouse lines, large multinodular tumors, having the typical morphological appearance of hepatocellular carcinomas, were observed (Fig. 4C) . Evidence of mitosis was seen in poorly differentiated hepatocytes (data not shown). One transgenic mouse (I-28H) had severe hepatic hyperplasia, with nodules of trabecular carcinoma but only minimal lipid deposits at 24 days. The plasma glutamic-oxaloacetic transaminase and glutamic-pyruvic transaminase levels were elevated in transgenic mice (data not shown).
The transgenic rabbit with 17 copies of the transgene appeared normal at birth but grew more slowly than its nontransgenic littermate. After 8 weeks, it became weak and immobile and, therefore, was euthanized. The transgenic rabbit's weight was -50% of that of its littermate (1160 g vs. 2250 g). Necropsy revealed an enlarged liver, weighing -1.5 times more than that of its nontransgenic littermate (112 g vs. 72 g). The transgenic rabbit's liver had visible scarring, fibrosis, and abnormal nodules on the surface. Histologically, the liver was characterized by distorted architecture, fibrosis, and cytoplasmic lipid droplets (Fig. 4D) .
In the transgenic rabbit founder, as in the mice, APOBEC-1 mRNA was expressed mainly in the liver (data not shown). Primer-extension analysis showed that 78% of the apo-B mRNA was edited in the transgenic rabbit liver, whereas no significant editing of apo-B mRNA occurred in the control rabbit liver (Fig. 1) . Although fasted plasma from normal rabbits contains only apo-B100, the lipoproteins isolated from the high copy number transgene rabbit contained >50% apo-B48 (data not shown).
The introduction of APOBEC-1 into the liver by gene transfer has the potential to be a powerful technique in lowering plasma LDL and lipoprotein(a) concentrations. Recently, Teng et al. (7) demonstrated that adenovirus-mediated transfer of rat APOBEC-1 into the livers of mice increased hepatic apo-B mRNA editing activity and lowered the concentration of lipoproteins containing apo-B100. Because apo-B mRNA editing is endogenously present in the livers of several mammals, it has been assumed that APOBEC-1 activity is innocuous. Moreover, it has been suggested that the editing activity resulting from the genetic transfer of APO-BEC-1 into the liver of an animal normally lacking editing activity also would be harmless (7). However, our study using transgenic animals clearly demonstrates that the overexpression of APOBEC-1 in the liver can be genotoxic.
The hepatic abnormality and transformation depended upon the overexpression of apo-B mRNA-editing activity and was not due to vector insertion, transforming elements in the vector, or the increased formation of apo-B48 in the transgenic animals. The occurrence of dysplasia in all four independent transgenic mouse lines and in a transgenic rabbit indicates that this change was not the result of insertion effects of the transgene. Transgenic mice with a mutant, enzymatically inactive form of APOBEC-1 ligated into the pLIV11 vector had normal livers (Table 1) . The same vector has been used to generate transgenic mice and rabbits expressing either human hepatic lipase or human apo-E, with no evidence of liver abnormality (20). Furthermore, gene targeting in embryonic stem cells has been used to generate mice that synthesize only apo-B48 (23). These "apo-B48-only" mice develop normally and have livers that are normal in size and morphology (R. V.
Farese, Jr. and S. G. Young, personal communication). Histological analysis of the livers of six apo-B48-only mice (aged 144-260 days) showed no abnormalities, in contrast to what we observed in the APOBEC-1 transgenic mice, and their plasma glutamic-oxaloacetic transaminase and glutamic-pyruvic transaminase levels were normal.
We postulated that the mechanism for the dysplasia in the APOBEC-1 transgenic animals is the aberrant editing of other mRNAs. A specific 11-nt mooring sequence in apo-B mRNA occurring 5 nt downstream from C6666 is critical for editing in vitro (24, 25) . When the mooring sequence is inserted into another location on apo-B or non-apo-B cDNA, the resulting chimeric RNA is edited in vitro, raising the possibility that mRNA with the mooring sequence and a cytidine 3-6 nt upstream could be edited in vivo (9, 10, 24, 25) .
A
To identify candidate mRNAs, we searched the GenBank for sequences similar to the mooring sequence using the FASTA program (26). Twenty-three rodent sequences were found to have the exact mooring sequence. Among these are the mouse fatty acid synthase (27) and mouse P1 protein (28), both of which contain a cytidine residue 4-6 nt upstream from the mooring sequence (Fig. SA) . Furthermore, >100 sequences were identified with sequence motifs just 1 nt different from the mooring sequence. These include mouse protein-tyrosine kinase TEC (29) and mouse prostaglandin synthase (30), which contain a cytidine residue 5 or 7 nt upstream from the mooring sequence, respectively (Fig. SA) .
To determine whether these mRNAs are edited in vivo, RNAs isolated from control and transgenic mouse livers were amplified by reverse transcription-PCR. The PCR products were analyzed for editing by primer-extension analysis (Fig.  SB) . None of the four mRNAs was edited in the livers of control mice, suggesting that the mooring sequence normally is not sufficient to support editing. Even in transgenic mice with high hepatic editing levels, three of the transcripts were not edited. However, mouse protein-tyrosine kinase TEC was edited in transgenic mice (Fig. SB) showed a decrease in (3-migrating LDL and a a-migrating high density lipoproteins (Fig. 6B ). indicate that a more physiological level of express editing activity can alter the ratio of LDL to lipoprotein cholesterol concentrations.
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